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Tuberous sclerosis complex (TSC) is a multi-system genetic disorder 
with a birth incidence around 1:5 800.[1,2] It affects ~1.5 million 
people around the globe with no obvious differences in prevalence 
based on gender or ethnicity, although epidemiological data from 
Africa, including South African (SA) populations, are lacking.[1,2] 
TSC can affect almost any organ system in the body, including the 
brain, heart, skin, kidneys and lungs. The greatest morbidity and 
mortality is associated with neurological, neuropsychiatric and 
renal manifestations.[2] To reduce the morbidity and mortality in 
TSC, evidence-based management and co-ordination of care across 
medical specialties is crucial throughout the lifespan of the patient.[2,3]
TSC was first described in 1880 by the French neurologist 
Bourneville at the Salpetriere Hospital in Paris. Bourneville had a 
15-year-old patient with severe intellectual disability and intractable 
epilepsy. After the death of the child, postmortem examination 
revealed unusual white, hard lesions on the cortical surface of the 
brain, and multiple small nodules lining the ventricular surface 
of the brain. Bourneville described these white, hard lesions as 
‘sclereuse tubereuse’ (white, potato-like lesions) of the cerebral cor-
tex. [2] Previously used terms for TSC include ‘Bourneville’s disease’ 
and ‘epiloia’, but use of these terms is now strongly discouraged.
The early diagnostic criteria, first documented in 1979, were 
based purely on the systematic clinical observations of Dr Manuel 
R Gomez, a physician at the Mayo Clinic in Rochester, USA. [4,5] 
Gomez identified that patients with TSC had a wide range of physical 
manifestations across almost all organ systems, including the brain, 
skin, heart, eyes, kidneys and lungs, and that multi-system involvement 
was highly variable between patients. He also recognised (in contrast to 
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the late 19th-century descriptions, where all patients were believed to 
have intellectual disability) that the intellectual abilities of individuals 
with TSC were extremely varied, ranging from normal intellectual 
ability to profound intellectual disability. Gomez’s observations remain 
at the heart of the diagnostic criteria and treatment guidelines for TSC, 
even in the most recent international revisions.[3,6]
Very little was understood about the patho physiology of TSC until 
the 1990s and 2000s. The TSC1 gene (on chromosome 9q34) and 
the TSC2 gene (on chromosome 16p13.3) were identified in 1993 
and 1997, respectively, but it remained unclear how their protein 
products functioned intracellularly. [1,2] We now know that the 
TSC1 and TSC2 proteins form an intra cellular complex in all cells, 
upstream to a protein called the mammalian target of rapamycin, 
typically referred to by its abbreviation mTOR. Two of the key intra-
cellular functions of mTOR are protein synthesis and regulation of 
cell migration and proliferation. In a situation where either the TSC1 
or TSC2 gene is affected due to a mutation, the TSC1-TSC2 complex 
is therefore not able to inhibit or ‘put the brakes’ on the mTOR 
complex, leading to overgrowth in specific cells, causing the benign 
tumours that are seen in individuals with TSC.[2,7,8] Recognition of 
this fundamental role of the TSC proteins in cells has also led to the 
discovery of molecularly targeted treatments for TSC in the form 
of mTOR inhibitors. These agents reduce the ‘overactivation’ of 
mTOR that results from disruption of the TSC1-TSC2 complex. [2,7,8] 
Fig. 1 shows a graphic representation of intracellular signalling in 
TSC, indicating where the mTOR inhibitors have their molecular 
treatment target.
In about 70% of cases, TSC occurs due to ‘sporadic’ mutations 
(de  novo). In the remaining 30% of cases, the mutation is inherited in 
an autosomal dominant fashion, and is therefore ‘familial’. Indivi duals 
with TSC have a 50% chance of passing the mutated TSC gene on to 
their children. Unaffected parents with one child with TSC have an 
approximately 1% chance of having another child with TSC.[1-3]
The clinical presentation and needs  
of individuals with TSC
Patients with TSC can have a complex and changeable clinical 
presentation. Firstly, many different organ systems can be involved, 
but in a variable way, termed variable expression. For instance, 
some patients may have significant skin involvement but few brain 
manifestations; others may have little skin involvement but significant 
renal and brain involvement.
Secondly, TSC manifestations may present at different ages, termed 
age-related expression. For instance, cardiac rhabdomyomas may be 
identified with antenatal fetal ultrasound or in the first year of life. 
After that they tend to regress and disappear. In contrast, skin and 
renal manifestations are typically not present at birth, but gradually 
appear over the first 5 - 15 years of life.[1,2]
Given the variability of manifestations and the age-related 
expression, individuals with TSC may present to a range of healthcare 
professionals with signs and symptoms of possible TSC. Table 1 shows 
a list of clinical manifestations that may suggest possible TSC in a new 
patient. In the antenatal period, a fetus is most likely to be identified 
with possible TSC when cardiac rhabdomyomas are identified on 
ultrasound. There are also cases where central nervous system 
manifestations (such as cortical tubers) are identified antenatally. 
In the first few years of life, the most typical presentation of TSC is 
likely to be with seizures, in particular focal seizures and infantile 
(epileptic) spasms, often with an onset in the first 12 months of life. 
Many parents notice unusual jerky movements in their 2 - 9-month- 
old infant, and these spasm-like movements are often confused with 
colic. Clear-cut seizures typically lead to hospitalisation, neurological 
work-up and clinical diagnosis of TSC in the presence of at least two 
major diagnostic criteria of TSC (see later in the article).
After the first few years of life, children may present with 
skin manifestations such as facial angiofibromas or hypomelanotic 
macules (white patches), or with developmental or behavioural 
concerns. Autism spectrum disorder is seen in 40 - 50% of indivi-
duals with TSC, and TSC is seen in as many as 4% of children with 
autism spectrum disorder. For this reason, all children with autism 
spectrum disorder and epilepsy should be evaluated for possible TSC. 
Individuals with mild physical manifestations of TSC may present 
with skin, academic or mental health problems, or be identified 
when renal manifestations are picked up on an ultrasound/magnetic 
resonance imaging (MRI) scan by chance.
Individuals with TSC may develop a benign brain tumour called a 
subependymal giant cell astrocytoma (SEGA) that almost invariably 
arises in the lateral ventricle adjacent to the foramen of Monro and 
may present with raised intracranial pressure due to obstructive 
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Fig. 1. The pathophysiology of TSC. The figure shows the intracellular 
signal ling pathways involved in TSC. Under normal conditions the 
TSC1- TSC2 complex inhibits mTOR, thereby regulating cell growth and 
proliferation. When a TSC1 or TSC2 mutation exists, the TSC1-TSC2 
complex is disrupted, which removes the inhibition on mTOR, leading to 
over-activation of mTOR signalling. This mTOR overactivation results in 
tumour formation, with cell growth and proliferation, as seen in the disorder. 
mTOR inhibitors counteract the overactive mTOR signalling, thus reduc-
ing inappropriate cell growth and proliferation. (Arrowhead = activating 
protein; flat head = inhibitory protein; 4E-BP1 = eukaryotic initiation 
factor 4E binding protein 1; AKT = protein kinase B; AMPK = adenosine 
monophosphate activated protein kinase; eIF4E = eukaryotic translation 
initiation factor 4E; ERK1/2 = extracellular signal regulated kinase 1 and 
2; GSK3β = glycogen synthase kinase 3-beta; HIF1α = hypoxia-inducible 
factor 1-alpha; LKB1 = serine/threonine kinase 1; MK2 = MAPK-activated 
protein kinase 2; mTORC1 = mammalian target of rapamycin complex 1; 
NF1 = neurofibromin, protein product of NF1 gene; p38MAPK  = p38 
mito gen-activated protein kinase; PI3K = phosphoinositide 3 kinase; 
PTEN  = phosphatase and tensin homolog; Ras = Rat sarcoma, a small 
GTPase protein; REDD1 = REgulated in Development and DNA Damage 
responses 1; Rheb = Ras homologue enriched in brain; S6K1 = ribosomal 
p70 S6 kinase 1; TSC1 = tuberous sclerosis complex 1 protein (hamartin); 
TSC2 = tuberous sclerosis complex 2 protein (tuberin). Different colours 
indicate different signalling path ways.)
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hydrocephalus. It is therefore possible that 
presentation and diagnosis of a SEGA will 
lead to comprehensive clinical work-up and 
diagnosis of TSC.
Adolescent boys or young men with TSC 
are sometimes diagnosed when they have a 
skin rash (often misdiagnosed as acne) that 
causes profuse bleeding during shaving. Some 
young people and adults present with ungual 
growths on their hands or feet that cause 
embarrassment or discomfort.
A proportion of mildly affected individuals 
with TSC are only diagnosed when they have 
a child diagnosed with TSC, or when there is 
a family history of TSC and a child receives 
comprehensive physical work-up.[1-3,6,8]
Given the variability of manifestations 
and the age-related onset, it is clear that 
individuals with TSC have both clinically 
complex and multi-system needs that will 
require input from a range of healthcare 
professionals across their lifespan. Patients 
therefore require a multidisciplinary diag-
nostic, monitoring and treatment approach 
using evidence-based intervention strate-
gies. [2,3,8] In SA, the majority of patients 
with TSC are likely to present to and be 
managed by general practitioners rather 
than by specialists. For this reason, it is of 
utmost importance for generalist and primary 
care teams to be aware of the best-practice 
guidelines for the assessment, monitoring and 
treatment of TSC.
Revision of the 
international 
diagnostic criteria and 
consensus guidelines 
for monitoring and 
treatment of TSC
As listed above, the first set of diagnostic 
criteria were generated by Gomez in 1979, 
based on his observations at the Mayo Clinic. 
By 1998, the TSC clinical and research 
community had grown, and a decision was 
made to have a conference in the USA 
with the aim of revising and generating 
international consensus on diagnostic cri-
teria and treatment. The meeting was 
attended by 23 TSC experts from four 
countries, and recommendations were based 
on majority views of expert opinion. The 
meeting resulted in publication of the first 
set of consensus diagnostic criteria,[4] often 
referred to as the ‘Roach criteria’. In addition, 
a consensus document on treatment and 
monitoring was published.[5] 
The genes for TSC had been identified by 
the time of the 1998 consensus conference, 
but little more was known about the biology 
of TSC, and no disorder-specific treatments 
were available. In 2003, the link between 
TSC1-TSC2 and mTOR was established, 
which rapidly led to clinical trials of 
mTOR inhibitors for TSC. In 2006, David 
Table 1. When to suspect TSC: Some suggestive clinical signs and symptoms
Family history
• A family history of TSC may lead to comprehensive physical work-up and diagnosis of the 
disorder
Antenatally
• Cardiac rhabdomyoma on fetal ultrasound or fetal MRI
• Cortical dysplasias such as cortical tubers or SENs on fetal ultrasound or fetal MRI
First 5 years of life
• Hypomelanotic macules (white patches) on the skin (distinct from vitiligo in that 
melanocytes are present in normal numbers in TSC hypomelanotic macules) (Fig. 3)
• Epilepsy, particularly infantile spasms (infantile spasms do not have to be accompanied by 
hypsarrhythmia)
• Cortical dysplasias such as cortical tubers, SENs or white-matter migration lines on MRI 
scan (these are unlikely to be visible on CT scan) (Fig. 3)
• Global developmental delay, particularly when accompanied by epilepsy
• Autism spectrum disorder, particularly when accompanied by epilepsy
• Treatment-resistant epilepsy
5 - 15 years
• SEGAs typically present in the 5 - 15-year age group. They may present with signs of raised 
intracranial pressure, but very often present with more subtle changes such as in behaviour, 
sleep or epilepsy control (Fig. 3)
• Facial angiofibromas (often diagnosed as acne) around the sides of the nose, but also on the 
chin, cheeks and forehead (Fig. 3)
• Renal angiomyolipomas on renal ultrasound or MRI scan (Fig. 3)
• Sudden deterioration in academic skills and onset of challenging behaviours such as aggression
• Specific learning disorders in school (particularly mathematics)
• Presentation of mood disorder or anxiety symptoms
15 - 25 years
• By now many of the clinical characteristics of TSC have developed. Young people identified 
for the first time at this age may present for a range of reasons, including skin concerns, 
epilepsy or epilepsy control, learning-related problems, emerging mental health problems, 
or increasing challenging behaviours in those with intellectual disability
• Ungual fibromas (on the fingers or toes) may present at this age (Fig. 3)
• Liver hamartomas may be identified for the first time at this age
• Visual problems associated with retinal hamartomas also have a slight increase in this age 
range (Fig. 3)
Adulthood
• Many mildly affected adults are only diagnosed with TSC when they have a child diagnosed 
with the disorder
• Adults who may have lived in more rural areas with less access to healthcare may present for 
the first time with any of the diagnostic characteristics of TSC, e.g. renal angiomyolipoma 
presenting with haemorrhage
• Adults with intellectual disability who move into care homes may be noted to have some of 
the physical characteristics of TSC, such as the facial angiofibromas or white patches (Fig. 3)
• Onset of mood and anxiety disorders in adulthood may lead to a mental health assessment 
where clinical features of TSC may be identified
Older adults
• Very little is known about the natural history of TSC in older adults
• It is unknown whether older adults with TSC have an increased risk of dementias or other 
neurocognitive disorders
• Older adults may be diagnosed when a grandchild with TSC is born, and a multi-generation 
clinical work-up is performed
Note: It is often a combination of features that raise suspicion of TSC, e.g. learning disorder 
in a child with a facial rash. Please note that this is not an exhaustive list of clinical 
presentations of TSC.
SENs = subependymal nodules; MRI = magnetic resonance imaging; CT = computed tomography; SEGA = subependymal 
giant cell astrocytoma.
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Franz and colleagues in Cincinnati showed that rapamycin (the 
prototypical mTOR inhibitor) could shrink SEGAs in TSC.[2] By 
2012, everolimus, another mTOR inhibitor, had received Federal 
Drug Administration and European Medicines Agency approval 
for the treatment of brain (SEGAs) and renal (angiomyolipoma) 
lesions in TSC.[2]
With the support of the National Institutes of Health (a research 
funding agency of the US Department of Health) and the Tuberous 
Sclerosis Alliance (a US advocacy and support organisation), a 
second consensus conference was convened in 2012, attended by 
79 TSC clinicians, researchers, individuals with TSC and parents, 
from 14 countries. The majority of the recommendations were 
based on evidence from peer-reviewed publications. This meeting 
resulted in a revised set of diagnostic criteria[6] and an enhanced 
set of management and surveillance guidelines.[3] Full details of 
the processes and procedures to generate relevant literature, review 
and weigh up (grade) evidence were presented clearly in the two 
core publications.[3,6] To summarise in brief, 12 subcommittees 
were organised to focus on specific disease areas. Subcommittees 
included a range of clinicians, researchers and parents/individuals 
with TSC. Each subcommittee had about 12 months to identify 
relevant questions, review the relevant literature, evaluate and 
weigh up the strength of data, and present an initial set of 
recommendations. Where consensus recommendations could not 
be made based on conflicting or lack of evidence, subcommittees 
were asked to provide recommendations for future research to 
answer these unresolved questions. A centralised literature search 
was performed for all subcommittees to use. The search included 
PubMed and Scopus databases between 1997 and 2012 (the year of 
the review). A total list of 2 692 articles were retrieved and provided 
to subcommittees. Subcommittees were also encouraged to add 
additional key literature based on specific subcommittee questions, 
if data provided in the central literature were insufficient. Evidence 
was evaluated and weighed up (graded) using the evidence-
based framework of the National Comprehensive Cancer Network 
Clinical Guidelines (all details provided in references).[3,6] Cate gory 1 
recommendations were based on high-level evidence and uniform 
consensus, category 2 recommendations were based on lower-level 
evidence and consensus, and category 3 recommendations were 
made where consensus could not be reached, regardless of evidence. 
All subgroups presented their recommendations at a 2-day overall 
consensus workshop where final consensus recommendations 
were made, from which the international guidelines were drawn 
up. All final recommendations were graded in the international 
publications. Interested readers are encouraged to read these 
documents.[3,6]
The diagnostic criteria and management guidelines were adopted 
internationally by TSC parent/user organisations and clinical groups, 
but the international consensus panel encouraged regional and 
national groups to consider the application and implementation of 
guidelines in local settings.
TSC in South Africa
Based on birth incidence and prevalence estimates for TSC and a mid-
year population estimate of 54 million South Africans in 2014, there 
are likely to be somewhere between 5 000 and 10 000 people with TSC 
in SA. While these numbers may not sound significant in the context 
of our many other health challenges, the complex, lifelong and multi-
system nature of TSC leads to an extremely high burden of disease, a 
high burden of care and treatment, and a very significant impact on 
disability and health economics.
However, very little is known about TSC in SA. There are no 
epidemiological data on the prevalence or incidence of TSC in this 
country, and no national registry or national organisation exists. 
Red Cross War Memorial Children’s Hospital in Cape Town has, to 
our knowledge, the only dedicated TSC clinic in the country, which 
includes ~80 - 100 patients. Collectively, the TSC experts and consensus 
working group members who drafted this consensus clinical update are 
involved in the monitoring and treatment of no more than 200 patients 
across SA. This observation suggests that the majority of individuals 
with TSC in SA are cared for in either general practice or non-specialist 
settings in the state or private sector, or may not even have reached 
medical services to receive diagnosis and treatment.
It is unclear how much healthcare professionals in SA know 
about TSC. Given the fact that it is a rare disease, many healthcare 
professionals may not be exposed to patients with TSC during their 
undergraduate or clinical training, or even during specialisation. 
Many nurses, psychologists, occupational and speech and language 
therapists, and other community-based practitioners are unlikely 
to receive training on recognition of the clinical manifestations of 
TSC. There is a great need for multidisciplinary teams in SA for the 
assessment, monitoring and treatment of the disorder.
Two of the key changes in the 2013 diagnostic and treatment 
guidelines for TSC involved the introduction of molecular genetic 
testing as a ‘genetic diagnostic criterion’ for TSC, and introduction 
of mTOR inhibitors for the treatment of specific manifestations of 
the disorder.[3,6] There are at present no clinical laboratories in SA 
that can do mutation analysis to establish a molecular diagnosis of 
TSC. Samples have to be sent to the USA, the UK or Europe for 
clinical molecular genetic testing. No mTOR inhibitors have received 
marketing authorisation in SA for any TSC-related indications to 
date. We are, however, aware of a number of individuals with TSC 
who are currently receiving mTOR inhibitors ‘off-label’ for various 
specific TSC indications.
The primary purpose of this SA consensus response to the 
international guidelines was to promote awareness of TSC among 
colleagues at primary healthcare level and specialists who may 
be involved in the care of affected individuals. Given that a well-
considered set of international guidelines had already been drawn 
up and published, we elected not to generate our own guidelines 
but rather to prepare a consensus clinical update in response to the 
internationally adopted guidelines.[3,6]
SA consensus clinical update 
in response to the 2013 revised 
diagnostic criteria and international 
guidelines for TSC
Given the clinical need of patients with TSC and the relative lack 
of expertise on TSC in SA, a decision was made to convene an SA 
consensus panel with the aim of developing a formal response to the 
international guidelines. The panel was led by PJdV, an international 
TSC expert, and included healthcare professionals with experience 
in the management of TSC from across SA. In the context of the 
two-tier healthcare system in the country, we deliberately included 
clinicians from both the state and private sectors. All panel members 
were provided with the two consensus articles[3,6] and were asked 
to review all recommendations. Each panel member was asked to 
indicate agreement or disagreement with each of the recommendations 
independent of other experts, and the results were collated by one of 
the authors (LL). A face-to-face consensus meeting took place on 
17 July 2014 in Johannesburg, with all the authors except one (BS) 
present. At the consensus meeting, the background and rationale of the 
CME
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meeting was presented by PJdV, all areas of consensus and disagreement 
were discussed, and a plan of action for next steps was generated.
Overall, the SA consensus group endorsed the two articles, with 
comments and caveats about resource implications and implementa-
tion into practice as outlined below.
A clinical flowchart for the diagnosis, 
monitoring and treatment of TSC 
(Fig. 2) 
Once the first clinical suspicion of TSC has presented (see Table 1 
for examples), patients require a comprehensive physical work-up as 
outlined in Table 2.[3] The primary purpose of clinical assessment is to 
determine whether a patient with ‘possible’ TSC has sufficient clinical 
manifestations to meet criteria for ‘definite’ TSC. The diagnostic 
criteria are presented in Table 3.[6] As highlighted above, a molecular 
diagnosis of TSC can now be made when an accredited clinical 
laboratory identifies a disease-associated mutation in TSC1 or TSC2. 
Many mutations identified in clinical molecular laboratories around 
the world are of unclear significance, and may represent non-disease-
associated polymorphisms (i.e. changes in the DNA sequence with an 
unclear consequence with regard to protein structure and/or function).
Given that SA has no clinical laboratories that can do mutation 
analysis for TSC, the consensus panel recommended that efforts 
should be made to introduce molecular genetic testing into a suitable 
SA clinical laboratory. In the meantime, SA clinicians should use the 
clinical diagnostic criteria to determine whether a patient meets the 
criteria for the disorder.
A patient meets the criteria when they have clinical evidence of two 
major diagnostic criteria for TSC (Table 3) or if they meet one major 
and two or more minor criteria. Fig. 3 illustrates some of the common 
diagnostic characteristics of TSC.
Once a patient has been diagnosed with TSC, they will require 
appropriate treatment based on their clinical manifestations and needs. 
Table 4 sets out the international treatment guidelines for TSC.[3]
The SA expert panel recognised that a number of the treatment 
and monitoring recommendations may be hard to access in a 
resource-limited SA setting, such as in accessing annual MRI 
scans of the brain, or electro-encephalograms. However, we were 
encouraged to hear that some SA centres were able to follow the 
international consensus recommendations. We therefore agreed that 
these international guidelines should be seen as an aspirational set of 
recommendations.
Ongoing monitoring of all patients with TSC is required, even 
if they had no overt problems or concerning manifestations at a 
previous clinic visit. Given the known age-related expression, patients 
may develop a range of clinical difficulties over a relatively short 
period of time. The international guidelines for regular monitoring 
of patients with TSC are presented in Table 5.[3]
Rapid assessment and treatment is required where patients present 
with sudden changes in clinical presentation. Examples of ‘change’ 
may include changes in seizure control or pattern, appearance of 
focal neurological signs, deterioration in school performance, or 
behavioural change (e.g. an individual who has a change in sleep 
or mood or becomes disruptive without obvious reason). Physical 
work-up should be prioritised and careful consideration given to 
the possibility of a SEGA, renal complications or other physical or 
metabolic abnormality.
Frequently asked clinical questions 
about diagnosis, monitoring and 
treatment in SA
During the preparation of this article, a number of questions 
emerged from within the consensus panel and from other clinical 
stakeholders in SA. We address some of the key questions here.
• Do we need to do MRI scans of the abdomen every 1 - 3 years, or 
is there a safe alternative in SA? Given that the majority of patients 
with TSC will develop renal angiomyolipomas associated with 
hypertension, pain and risk of haemorrhage, early identification 
and treatment of renal lesions is essential. Identification of renal 
lesions is therefore the primary reason for abdominal imaging. In 
order to understand and treat the renal lesion, we need to know 
what is there and how big it is. TSC renal lesions are often of 
odd shapes and fat-poor, making it very difficult to visualise and 
measure their size accurately. Ultrasound has been assessed in 
the literature, and has been shown not to be sufficiently accurate 
for use in TSC and polycystic disease. Apart from renal lesions, 
it is also important to detect additional TSC-related findings in 
the liver, aorta/blood vessels, spleen, pancreas, etc., all of which 
can be identified in patients with TSC during MRI surveillance 
of the kidneys. These TSC manifestations are not detected or 
evaluated with renal ultrasound. For these reasons, the evidence-
based recommendation for renal and abdominal monitoring is 
abdominal MRI every 1 - 3 years.
• Do we need an MRI scan of the brain every 1 - 3 years, or will 
a computed tomography (CT) scan be sufficient? CT scans are 
not recommended in TSC for two reasons: (i) the need for serial 
imaging from early childhood into adulthood poses real concern 
about unnecessary cumulative exposure to ionising radiation when 
a non-exposure alternative (MRI) exists; and (ii) MRI is superior 
to CT at detecting soft-tissue components of SEGAs, especially 
when tumours are only partially calcified. While a SEGA may be 
diagnosed on a CT scan, especially if there is a calcified component, 
MRI with post-contrast sequences is better able to define the 
tumour margin and the relationship to important structures such 
as the foramen of Monro, fornix and blood vessels, and is also a 
more reproducible means of measuring and monitoring tumour 
size over time.
Clinical suspicion of TSC
(see Table 1)
Perform a clinical 
work-up for TSC 
(see Table 2)
Implement appropriate 
evidence-based treatment
(see Table 4)
Monitor manifestations of 
TSC as recommended
(see Table 5)
TSC conrmed using 
diagnostic criteria
(see Table 3)
Fig. 2. A clinical flow-chart for the diagnosis, monitoring and treatment of TSC.
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• Can we combine MRI of the abdomen and brain in a single session? We 
strongly recommend that MRI of the abdomen and brain is co-ordinated 
between neurology, nephrology and radiology teams to ensure that patients 
only need to come for a single MRI session. This may be particularly use -
ful for patients who require sedation or an anaesthetic for the procedure.
• How important are neurodevelopmental assessments in TSC? Many 
people with TSC have neurodevelopmental difficulties, but many 
do not receive regular and detailed assessments. For this reason, 
we strongly support the international recommendations to perform 
annual screening for neurodevelopmental difficulties as part of a 
Table 2. Consensus guidelines for baseline work-up of newly identified patients with possible TSC (modified from Krueger et al.,[3] with permission)
Organ system or 
specialist area Recommendation
Genetics • Obtain a three-generation family history to assess for additional family members at risk of TSC
• Offer genetic testing and family counselling
• Genetic testing is not available in SA. However, where a TSC diagnosis is in question but cannot be clinically confirmed, 
genetics services could consider requesting genetic testing from an international clinically accredited laboratory
Brain • Regardless of the age of the patient at diagnosis, perform MRI of the brain (with or without gadolinium enhancement) to 
assess for presence of cortical/subcortical tubers, SENs, migrational defects and SEGAs
• If MRI is not available or cannot be performed, CT or head ultrasound (in neonates or infants with open fontanelles) may 
be used, although results are considered suboptimal and will not always be able to detect abnormalities revealed by MRI
• For parents with infants, educate parents to recognise infantile spasms, even if none have occurred at the time of first 
diagnosis
• Obtain baseline routine EEG, even in the absence of recognised or reported clinical seizures. If baseline EEG is abnormal, 
especially if features of TAND are also present, follow up with a 24-hour video EEG to assess for subclinical seizures, 
wherever possible
TAND • Evaluate for TAND. All patients should receive a comprehensive assessment at diagnosis as a baseline for future evaluations 
and to identify areas requiring immediate or early intervention
• Comprehensive evaluation should include detailed neurodevelopmental assessment, and assessment for behavioural, 
psychiatric, learning, neuropsychological and psychosocial concerns
• In particular, ensure evaluation for intellectual disability, autism spectrum disorder, ADHD, anxiety and depressive disorder
• Comprehensive assessment is likely to require multidisciplinary involvement
• Clinical teams should maintain a low threshold to initiate early intervention and other management strategies
• Patients of school-going age should be considered for an IEDP
Kidneys • MRI of the abdomen to assess for the presence of angiomyolipoma and renal cysts
• Many angiomyolipomas are fat-poor and hence missed on CT or ultrasound
• Screen for hypertension by obtaining accurate blood pressure
• Evaluate renal function by determining GFR. Paediatric GFR can be derived from a calculated Schwartz formula
Lungs • Perform baseline lung function testing (including a 6-minute walk test) and HRCT in patients at risk of LAM, even if 
asymptomatic. At-risk patients are typically females over the age of 18 years. Symptomatic male adult patients should also 
undergo testing
• Aim to use low-radiation HRCT protocols wherever possible
• VEGF-D level may be helpful to establish a baseline for future LAM development or progression in at-risk patients at 
around the age of 18 years
• Provide counselling to adolescent and adult females on the adverse impact of smoking and oestrogen use (such as oral 
contraceptives) on LAM
Skin • Perform a detailed clinical dermatological examination to look for angiofibromas, fibrous cephalic plaques, hypomelanotic 
macules or confetti lesions, ungual fibromas and shagreen patch
Teeth • Perform a detailed clinical dental examination to look for defects in tooth enamel and intraoral fibromas
Heart • Where rhabdomyomas are identified during prenatal testing, consider fetal echocardiography to detect individuals at high 
risk of heart failure after delivery
• Obtain an echocardiogram and ECG in paediatric patients, especially aged <3 years, to assess for rhabdomyomas and 
arrhythmia, respectively
• Obtain an ECG in all ages to assess for underlying conduction defects that may be present, and may influence medication 
choice and dosing
Eyes • Perform a comprehensive opthalmological examination, including dilated fundoscopy, to assess for hamartomas or 
hypopigmented lesions of the retina, and for visual field defects
Other • Although vascular aneurysms, gastrointestinal polyps, bone cysts and various endocrinopathies may be seen in TSC, there 
is insufficient evidence to recommend routine evaluation at the time of diagnosis, unless clinical symptoms or a concerning 
history warrants specific additional investigations
Note: All the investigations listed above should be performed by appropriately qualified professionals acting within their field of competence. 
The table outlines the need for multidisciplinary, multiprofessional work in TSC.
SENs = subependymal nodules; CT = computed tomography; EEG = electroencephalogram; TAND = TSC-associated neuropsychiatric disorders; 
ADHD = attention deficit hyperactivity disorder; IEDP = individual education development plan; GFR = glomerular filtration rate; HRCT = high-resolution chest CT; 
LAM = lymphangioleiomyomatosis; VEGF-D = serum vascular endothelial growth factor type D; ECG = electrocardiogram.
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broader evaluation of all TSC-associated neuropsychiatric disorders 
(TAND).[3,9] We also strongly support the international recommen-
dation to perform regular detailed neurodevelopmental and mental 
health assessments at key timepoints, as shown in Table 5.
• Is it important to screen for and assess for autism spectrum 
dis order? TSC is the medical condition most strongly associated 
with autism spectrum disorder. Almost 50% of people with TSC 
meet criteria for autism spectrum disorder, and many have social-
communication difficulties even if they do not meet criteria for 
autism spectrum disorder. For this reason, it is very important to 
screen for autism spectrum disorder from early on, and to do a 
comprehensive diagnostic work-up if there are any concerns. The 
TAND Checklist[9,10] was designed as a simple pen-and-paper tool 
to help clinicians screen for autism spectrum disorder and other 
TAND.
• Are formal assessments required to assist with school placements 
for children with TSC? Even though children with TSC can 
have a huge range of intellectual abilities, the rates of scholastic 
difficulties are very high.[2,9] Many children with TSC, even when 
they have normal or above-average IQs, have specific learning 
disorders that will affect their ability to achieve in school. It is 
also important to remember that any aspect of TAND can affect a 
child’s ability to access learning, e.g. attention deficit hyperactivity 
disorder (ADHD), autism spectrum disorder, anxiety or depressive 
disorders, specific neuropsychological deficits, and psychosocial 
factors. For this reason, we strongly support the international 
recommendations that all school-aged children should be assessed 
for their educational needs and for the potential need for an 
individual education development plan (IEDP) (Table 4).
Recommendations for next steps to 
support individuals with TSC in SA
Given the discrepancy between needs of patients with TSC and 
available resources and expertise in SA, the SA consensus panel 
made a number of recommendations for implementation in SA 
(Table 6). We strongly endorsed the dissemination and use of 
the international guidelines for the assessment, monitoring and 
treatment of TSC. In addition, we strongly support access to genetic 
testing, which is increasingly used around the world in clinical 
genetics settings to do preimplantation testing, and to examine the 
association between genotype and phenotype. At present, there are 
no clinical recommendations regarding differences between TSC1 
and TSC2 mutations, but there is significant research interest in the 
use of genotypic information to predict phenotype and potential for 
treatment response.[11,12]
We also strongly advocate for the relevant regulatory bodies in SA to 
provide marketing authorisation and reimbursement to support access 
to mTOR inhibitors for patients in SA for all internationally approved 
indications. Everolimus, one of the mTOR inhibitors, received market-
ing authorisation in the USA and Europe for the treatment of SEGAs 
not amenable to surgery, and for renal angiomyolipomas larger than 
3 cm.[3] Recently, everolimus also received marketing authorisation 
Table 3. Revised diagnostic criteria for TSC (Northrup et al.,[6] reproduced with permission) 
A. Genetic diagnostic criteria
The identification of either a TSC1 or TSC2 pathogenic mutation in DNA from normal tissue is sufficient to make a definite diagnosis of TSC. 
A pathogenic mutation is defined as a mutation that clearly inactivates the function of the TSC1 or TSC2 protein (e.g. out-of-frame indel or 
nonsense mutation), prevents protein synthesis (e.g. large genomic deletions), or is a missense mutation the effect of which on protein function 
has been established by functional assessment (see the LOVD databases for TSC1 (http://www.lovd.nl/TSC1) and TSC2 (http://www.lovd.nl/
TSC2)). Other TSC1 or TSC2 variants with less certain effects on function do not meet these criteria, and are not sufficient to make a definite 
diagnosis of TSC. Note that 10 - 20% of TSC patients have no mutation identified by conventional genetic testing, and a normal result does 
not exclude TSC or have any effect on the use of clinical diagnostic criteria to diagnose TSC. Where genetic testing is not available, the clinical 
criteria are used to diagnose TSC.
B. Clinical diagnostic criteria
Major features
• Hypomelanotic macules (≥3, at least 5 mm diameter)
• Angiofibromas (≥3) or fibrous cephalic plaque
• Ungual fibromas (≥2)
• Shagreen patch
• Multiple retinal hamartomas
• Cortical dysplasias (these include tubers and cerebral white matter radial migration lines)
• SEN
• SEGA
• Cardiac rhabdomyoma
• LAM*
• Angiomyolipomas (≥2)*
Minor features
• ‘Confetti’ skin lesions
• Dental enamel pits (>3)
• Intraoral fibromas (≥2)
• Retinal achromic patch
• Multiple renal cysts
• Non-renal hamartomas
Definite diagnosis: Two major features or one major feature plus ≥2 minor features
Possible diagnosis: Either one major feature or ≥2 minor features
SEN = subependymal nodule; SEGA = subependymal giant cell astrocytoma; LAM = lymphangioleiomyomatosis.
*A combination of these two major features without other features does not meet criteria for a definite diagnosis of TSC.
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Other manifestations
Skin manifestations
Brain manifestations
Hypomelanotic macule 
(white patch) 
                     Shagreen patch           Ungual fibroma
Facial angiofibromas Facial angiofibromas  Fibrous cephalic plaques
   Cortical tubers (black arrows)   Subependymal nodules  
(white arrows)
Subependymal giant cell 
astrocytoma (white arrow)
Retinal hamartoma Bilateral renal  
angiomyolipomas
        Lymphangioleiomyomatosis (LAM)
Fig. 3. Clinical manifestations of TSC. The images are reproduced with the permission of Dr J Chris Kingswood (UK) and Dr Raj Newaj (SA).
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in Europe for the adjunctive treatment of refractory focal seizures, 
following results of an international multi-centre trial.[13] In addition, 
topical preparations are used for facial angiofibromas and other skin 
manifestations with very positive outcomes. There is also evidence 
that systemic mTOR inhibition improves skin manifestations in 
patients who take mTOR inhibitors for SEGAs or angiomyolipomas. 
A number of clinical trials are underway exploring the potential 
for mTOR inhibitors to improve TAND such as autism, intellectual 
disability, academic difficulties or specific neuropsychological 
deficits.[2]
Apart from clinical aspects of TSC, we also recommend its 
inclusion in undergraduate and postgraduate medical and health 
sciences curricula, and the promotion of other continuous profes-
sional development events to raise awareness about it. We support 
the development of a TSC user/carer/parent organisation that can 
develop into an informal support network for families across SA. 
TSC International (TSCi) is a worldwide network of user/carer 
organisations (http://www.tscinternational.org), and it would be a 
very powerful strategy to connect the SA TSC community to TSCi. 
We strongly support ongoing research on TSC in SA and other 
African countries, given the clear need, but lack of local research 
data.
In high-income settings, it is standard practice for an individual with 
TSC to be seen by a range of specialists, including paediatric neurology, 
Table 4. Consensus guidelines for the treatment of TSC (modified from Krueger et al.[3] and adapted for the SA context)
Organ system or 
specialist area Recommendation
Genetics • Individuals with TSC who reach reproductive age should be offered genetic assessment and genetic counselling
• First-degree relatives of affected individuals should be offered clinical assessment, and where a mutation has been identified 
in the index case, genetic testing should be offered
• There is no direct access to genetic testing for TSC in SA at present. Specific requests should be discussed directly with 
clinical genetics experts, who may be able to explore access to international, clinically accredited laboratories
Brain • Acutely symptomatic SEGA. Surgical resection should be performed for acutely symptomatic SEGAs. Cerebrospinal fluid 
diversion (shunt) may also be necessary
• Growing but otherwise asymptomatic SEGA. Either surgical resection or medical treatment with mTOR inhibitors may 
be used. The shared decision-making process with families should consider complication risks, adverse effects, cost of 
treatment, expected length of treatment, potential impact of TAND and family preference
• Infantile (epileptic) spasms. Vigabatrin is recommended as the first-line treatment for infantile (epileptic) spasms. ACTH 
may be considered when treatment with vigabatrin is unsuccessful
• Other seizure types. Antiepileptic drug therapy should follow that of other epilepsies
• Refractory seizures. Epilepsy surgery and VNS may be considered for children with medically refractory seizures. Special 
consideration should be given to children at young ages with neurological regression. Epilepsy surgery and VNS are 
best performed at epilepsy centres with experience and expertise in TSC. Ketogenic and related diets may have a place 
in management, but the evidence is limited.[2] mTOR inhibitors have recently been approved as adjunctive treatment for 
partial-onset seizures.[13]
TAND • Management strategies should be based on the TAND profile of each patient and should be based on evidence-based, good 
practice guidelines/practice parameters for individual disorders (e.g. autism spectrum disorder, ADHD, anxiety disorder)
• All school-aged children should be considered for an IEDP
• Sudden change in behaviour should prompt medical/clinical evaluation to look at potential medical causes (e.g. SEGAs, 
seizures, renal disease)
Kidneys • Acute haemorrhage. Embolisation followed by corticosteroids is first-line treatment for angiomyolipomas presenting with 
acute haemorrhage
• Asymptomatic, growing angiomyolipomas >3 cm. An mTOR inhibitor is recommended as first-line treatment. Selective 
embolisation or kidney-sparing resection are acceptable second-line therapy for asymptomatic angiomyolipomas
• Nephrectomy should be avoided at all costs
Lungs • mTOR inhibitors may be used to treat LAM patients with moderate to severe lung disease or rapid progression
• TSC patients with LAM are candidates for lung transplantation, but the comorbidities of TSC may affect suitability for 
transplant. Lung transplantation for TSC has not been performed in SA
Skin • Rapidly changing, disfiguring or symptomatic TSC-associated skin lesions should be treated as appropriate for the lesion 
and clinical context. Approaches may include surgical excision, laser(s) or topical mTOR inhibitors
• Systemic mTOR inhibitors also have an impact on TSC-associated skin lesions, but are not recommended for skin lesions as 
a primary indication. Clinical trial evidence is awaited to inform recommendations regarding topical mTOR preparations
Teeth • Symptomatic or deforming dental lesions, oral fibromas and bony jaw lesions should be treated with surgical excision, 
curettage, or lasers
• Enamel defects (dental pits) can be treated with restorative treatments if the patient is at high risk for cavities, although they 
rarely cause symptoms or an increased rate of dental decay
Heart • Patients with clinical symptoms, including conduction defects and rhythm disturbances such as Wolff-Parkinson-White 
syndrome, may require more frequent monitoring and appropriate intervention
Eyes • Intervene as appropriate when clinical concern arises regarding visual symptoms and visual field defects
TAND = TSC-associated neuropsychiatric disorders; ACTH = adrenocorticotrophin hormone; VNS = vagus nerve stimulation; ADHD = attention deficit hyperactivity disorder; 
LAM = lymphangioleiomyomatosis.
CME
377       May 2017, Vol. 107, No. 5
dermatology, paediatric nephrology, psychiatry, psycho logy and so on. 
In an SA setting, we acknowledge that, owing to resource limitations, 
many patients with TSC may currently be cared for in primary or 
secondary care settings. We would, however, like to encourage referral 
to and appropriate liaison with tertiary services, particularly to teams 
with a particular interest in and experience working with individuals 
who have TSC. Patients with SEGAs, angiomyolipomas, hypertension, 
dermatological manifestations, epilepsy and neuropsychiatric disor-
ders should always be referred to specialists and, wherever possible, to 
tertiary settings. While general practitioners in SA may have a central 
Table 5. Consensus guidelines for ongoing monitoring of individuals with TSC (modified from Krueger et al.,[3] with permission)
Organ system or 
specialist area Recommendation
Genetics • If individuals with TSC reach reproductive age, or if a first-degree relative would like to consider having children, referral 
to a clinical genetics service should be made
• In families where there is an individual with TSC, other family members, including new ones, should be considered for 
the possibility of TSC
• At present, no genotype-phenotype correlations warrant any clinical recommendations
Brain • Perform an MRI scan of the brain every 1 - 3 years in asymptomatic patients aged <25 years to look for possible emerging 
SEGAs
• Asymptomatic patients with large or growing SEGAs causing ventricular enlargement should undergo MRI scans more 
frequently, and their families should be educated about potential new symptoms
• Patients with asymptomatic SEGAs in childhood should continue to be imaged periodically as adults to ensure that there 
is no growth
TAND • Screen for TAND at least annually. A free, downloadable TAND Checklist has been developed for this purpose[9]
• Formal evaluation for TAND should be performed at five key developmental time points: infancy (0 - 3 years), preschool 
(3 - 6 years), in the middle school years (6 - 9 years), in adolescence (12 - 16 years), in early adulthood (18 - 25 years), and 
as required after that
• Formal evaluation should include detailed neurodevelopmental assessment and assessment for behavioural, psychiatric, 
learning, neuropsychological and psychosocial concerns
Kidneys • Perform an MRI scan of the abdomen every 1 - 3 years from diagnosis, regardless of age, throughout the lifespan to assess 
the progression of angiomyolipomas and renal cystic disease
• Assess renal function (including GFR) and blood pressure annually
• Perform urinalysis for haematuria at each clinical visit
Lungs • Perform clinical screening for LAM symptoms (including exertional dyspnoea and shortness of breath) at each clinic visit
• Perform HRCT every 5 - 10 years in asymptomatic individuals at risk of LAM
• Individuals with lung cysts at baseline HRCT should have annual lung function tests and HRCT every 2 - 3 years
Skin • Perform a detailed clinical skin examination annually
Teeth • Perform a detailed clinical dental examination every 6 months
• Perform a panoramic radiograph by the age of 7 years, if not performed earlier
Heart • Perform an echocardiogram every 1 - 3 years in asymptomatic paediatric patients until regression of cardiac rhabdomyoma
• Symptomatic patients may require more frequent echocardiogram
• Perform an ECG every 3 - 5 years in asymptomatic patients of all ages to monitor for conduction defects
• More frequent or advanced diagnostic assessment (e.g. ambulatory and event monitoring) may be required for symptomatic 
patients
Eyes • Perform annual ophthalmological examination in patients with previously identified eye lesions or vision symptoms
• More frequent assessment (including of patients on vigabatrin) appears to be of limited benefit and is not recommended 
unless new clinical concerns arise
TAND = TSC-associated neuropsychiatric disorders; GFR = glomerular filtration rate; LAM = lymphangioleiomyomatosis; HRCT = high-resolution chest computed tomography; 
ECG = electrocardiogram.
Table 6. Recommendations of the SA TSC consensus meeting
1.    Endorse the Revised Diagnostic Criteria as recommended by the 2012 International Tuberous Sclerosis Complex Consensus Conference
2.    Endorse the Surveillance and Management Guidelines as recommended by the 2012 International Tuberous Sclerosis Complex  
Consensus Conference
3.    Support access to mutation analysis for TSC in SA
4.    Support access to mTOR inhibitor treatments for patients with TSC in SA in the state and private sectors
5.    Encourage inclusion of TSC into undergraduate and postgraduate medical and health sciences curricula
6.    Facilitate continuing professional development activities to raise awareness and knowledge about TSC
7.    Promote establishment of a user/carer/parent non-profit organisation for TSC in SA
8.    Promote establishment of an SA registry of TSC patients
9.    Promote research on TSC in SA and across the African continent
10.  Support development of specialist TSC multidisciplinary teams
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role in the overall co-ordination of care, we do not recommend that a 
general practitioner be expected to carry out clinical management of 
an individual with TSC in isolation. In SA, a shared-care approach with 
clear communication and liaison between generalists and specialists 
to build a virtual ‘team around the family’, with families as active and 
equal partners in this process, would be ideal.
We acknowledge that some positive progress has been made in 
recent years. A number of talks on TSC have been presented at local 
and national fora, and a number of SA-based publications have been 
produced. [10,14,15] In addition, SA is a participating country in the 
International Natural History Study of TSC, referred to as TOSCA 
(TuberOus SClerosis Registry to increase disease Awareness).[16] 
We sincerely hope that these SA guidelines will also make a positive 
contribution to increase knowledge and improve clinical care for all 
patients who live with TSC in SA, and their families.
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